AGIOS PHARMACEUTICALS, INC. Proceeds from Divestiture of Businesses
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Proceeds from Divestiture of Businesses of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2026-02-12
- AGIOS PHARMACEUTICALS, INC. proceeds from divestiture of businesses for the quarter ending 2025-12-31 was $0.00.
- AGIOS PHARMACEUTICALS, INC. proceeds from divestiture of businesses for the quarter ending 2024-12-31 was $0.00.
- AGIOS PHARMACEUTICALS, INC. proceeds from divestiture of businesses for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. proceeds from divestiture of businesses for fiscal 2024 was $200.00M.
- AGIOS PHARMACEUTICALS, INC. proceeds from divestiture of businesses for fiscal 2023 was $0.00.
- AGIOS PHARMACEUTICALS, INC. proceeds from divestiture of businesses for fiscal 2022 was $0.00.
| Period end | Proceeds from Divestiture of Businesses 3 month | Proceeds from Divestiture of Businesses 9 month | Proceeds from Divestiture of Businesses 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $0.00 10-K · filed 2026-02-12 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $200.00M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $200.00M 10-Q · filed 2025-10-30 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-12 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |